scholarly article | Q13442814 |
P50 | author | Mate Vamos | Q41121827 |
P2093 | author name string | Stefan H Hohnloser | |
Philipp Bushoven | |||
Sven Linzbach | |||
P2860 | cites work | ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation | Q22306351 |
Dabigatran versus warfarin in patients with atrial fibrillation | Q28256895 | ||
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society | Q29614693 | ||
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association | Q29614695 | ||
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
Apixaban versus warfarin in patients with atrial fibrillation | Q29617563 | ||
Termination of ventricular fibrillation in man by externally applied electric countershock | Q34538017 | ||
New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge | Q34540230 | ||
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. | Q34651036 | ||
Stroke severity in atrial fibrillation. The Framingham Study | Q34735226 | ||
Stroke prevention in atrial fibrillation: do we still need warfarin? | Q37964949 | ||
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence | Q40310174 | ||
Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation | Q43603177 | ||
Time course and frequency of subtherapeutic anticoagulation for newly prescribed warfarin anticoagulation before elective cardioversion of atrial fibrillation or flutter. | Q43821345 | ||
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial | Q44196299 | ||
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials | Q45139213 | ||
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. | Q51058191 | ||
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation | Q56620375 | ||
Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation | Q59313024 | ||
Subclinical Atrial Fibrillation and the Risk of Stroke | Q64452296 | ||
The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation | Q70105143 | ||
"Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients | Q79443159 | ||
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion | Q83104350 | ||
P433 | issue | 1 | |
P921 | main subject | atrial fibrillation | Q815819 |
cardioversion | Q1729126 | ||
anticoagulation | Q63279445 | ||
P304 | page(s) | 44-46 | |
P577 | publication date | 2015-03-10 | |
P1433 | published in | Arrhythmia & electrophysiology review | Q27727082 |
P1476 | title | Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation | |
P478 | volume | 4 |
Q36287783 | Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion | cites work | P2860 |
Search more.